Colorectal cancer

Genomic profiling of patients who were treated for colorectal cancer showed that patients with African ancestry had fewer actionable mutations than patients with European ancestry. These patients were also less likely to qualify for treatment with immunotherapy, according to data presented at the AACR Annual Meeting 2023. “African American patients are known to have worse […]

A Phase II trial to investigate onvansertib for the second line treatment of patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) has treated its first patients. The ONSEMBLE trial is designed to demonstrate a clinically meaningful difference in response and onvansertib’s contribution to standard of care (SoC) FOLFIRI/bevacizumab. “We are excited to be underway with our […]

Diana Spencer explores the different ways the drug discovery sector is tackling colorectal cancer. Colorectal cancer is preventable with screening and often treatable when caught early, yet due to late diagnosis and chemotherapy resistance, it remains the second deadliest cancer in the United States. Held in the US March every year, the aim of National […]

A team from the University of Geneva (UNIGE) has found a way to overcome chemotherapy resistance in colorectal cancer.  The team successfully used a combination of tyrosine kinase inhibitors, opening up new avenues for developing therapies that are more targeted than chemotherapy.  Colorectal cancer is one of the most common cancers. Over time, chemotherapy induces […]

News round-up for 12-16 September by DDW Digital Content Editor Diana Spencer A slightly quieter week for news in light of national events in the UK, but the vital work of the international drug discovery community goes on and new discoveries are being made all the time.  The last seven days have seen important breakthroughs […]

A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer. Findings from the SUNLIGHT trial have revealed that the combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in overall survival compared to trifluridine/tipiracil alone. The Phase III clinical trial studied participants with refractory metastatic colorectal cancer (mCRC) […]